Novartis is further bolstering its preclinical pipeline and continuing its hunt for a Xolair successor, nailing down a ...

Japan’s Kyorin Pharmaceutical has entered into a global license agreement with Swiss pharma giant Novartis relating to ...

In Regeneron Pharmaceuticals Inc.’s phase I/II Chord study of 12 children with genetic hearing loss tied to the variants of the otoferlin gene, 10 out of 11 have showed notable improvements in their ...

Last year Novartis unveiled Bertrand Bodson ... potential of our pipeline and deliver our next stage of growth.” Kyorin Pharma has signed a deal with Hyfe to develop a digital therapeutic ...

M223, a preclinical drug for inflammatory diseases, with potential milestone payments of $777.5M plus royalties.

IN8bio has unveiled a new T cell engager (TCE) platform, marking its first major push into autoimmune disease. The biotech, which previously focused on oncology, introduced INB-619, a CD19-targeted ...

Under this agreement, KYORIN obtains an option for the license of the right to develop and commercialize CYR-064 in Japan and will pay an option fee to Cyrano. Upon exercising the option and ...

DELRAY BEACH, Fla., Feb. 18, 2025 /PRNewswire/ -- Cyrano Therapeutics, Inc., a clinical-stage regenerative medicine company pioneering the development of treatments for smell loss, announced ...

After Novartis and Roche grew their sales last year, the Swiss pharma giants are handing their CEOs larger compensation packages for 2024. At Novartis, CEO Vas Narasimhan’s overall 2024 pay ...